TherapeuticsMD (TXMD) Operating Expenses (2010 - 2026)

TherapeuticsMD (TXMD) has reported Operating Expenses for 17 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 2.31% year-over-year to $1.7 million; the trailing twelve-month figure through Jun 2026 stood at $7.2 million (up 14.27% YoY), and the FY2025 full-year result was $7.4 million, down 5.86% from the prior year.
• Operating Expenses improved to $1.7 million in Q2 2026 per TXMD's latest filing, from $1.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $20.1 million in Q4 2022 and bottomed at $1.3 million in Q4 2024.
• Historically, Operating Expenses has averaged $5.3 million across 5 years, with a median of $1.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 125.87% in 2022, then plunged 89.5% in 2023.
• Over 5 years, Operating Expenses stood at $20.1 million in 2022, then slumped by 89.5% to $2.1 million in 2023, then slumped by 37.58% to $1.3 million in 2024, then jumped by 85.37% to $2.4 million in 2025, then sank by 31.08% to $1.7 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $1.7 million, $1.4 million, and $2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.